Lymphocyte subpopulations, levels of interferon, and expression of their receptors in patients with chronic hepatitis B and C: Correlation with the species of viruses and the degree of liver fibrosis


Cite item

Full Text

Abstract

Aim. To determine whether there is a correlation of the composition of circulating lymphocyte subpopulations, the serum concentrations of interferon (IFN)-α, IFN-γ, and IFN-λ3, and the lymphocyte expression of types I and II IFN receptors with the species of a disease pathogen and the degree of liver fibrosis (LF) in patients with chronic hepatitis B (CHB) and in those with chronic hepatitis C (CHC). Subjects and methods. The investigation enrolled 44 patients with CHC, 9 patients with CHB, and 13 clinically healthy donors. The degree of LF in the patients was determined using transient elastography. The composition of peripheral blood lymphocyte subpopulations was examined; the concentrations of IFN-α, IFN-γ, and IL-28B were estimated. Results. Lymphocyte counts were higher in patients with CHC and in those with CHB than those in healthy donors; and the number of neutrophils was lower. There were no differences between the groups in the composition of lymphocyte subpopulations with the exception of the number of CD3CD4cells, which in patients with CHC was larger than in those with CHB. In CHC and CHB patients, the counts of CD118lymphocytes were higher than those in healthy donors. Patients with CHB and those with CHC did not differ between themselves and from healthy donors in the expression of CD119 on the lymphocytes. In CHC patients, the relative CD119cell counts were higher between CD4lymphocytes than those in healthy donors. The serum levels of IFN-α and IFN-γ in CHC and CHB patients were similar, but higher in healthy donors. The concentration of IL-28B genotype in patients with CHC was twice as high as in those with CHB, but the differences were statistically insignificant. The number of lymphocytes increased with the progression of fibrosis; that of neutrophils decreased. There was an inverse relationship between platelet counts and LF severity. Multiple comparisons of the clusters of patients with different degrees of LF revealed no differences in the number of major lymphocyte subpopulations. However, the number of CD3CD16CD56natural killer-like T (NKT) cells correlated with fibrosis severity. Patients with different degrees of LF showed no differences in the proportion of CD118and CD119 cells between lymphocytes and in the serum levels of IFN-α, IFN-γ, and IL-28B levels. Patients with grade IV LF displayed a higher proportion of CD4CD119lymphocytes between CD45cells than did those with grade III LF. Conclusion. Several new clinical and laboratory trends were identified and the nature and extent of previously described hematological and immunological changes were clarified in CHC or CHB patients with various degrees of LF. Some indicators may be used as additional criteria for the prognosis of the above forms of hepatitis, and a number of newly described facts suggest that it is necessary to revise the protective/phlogogenic value of types I, II, and III IFNs in chronic viral hepatitis C and B.

About the authors

O V Kalyuzhin

ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России

Москва, Россия

Zh B Ponezheva

ФБУН ЦНИИ эпидемиологии Роспотребнадзора

Москва, Россия

I V Semenova

ФБУН ЦНИИ эпидемиологии Роспотребнадзора

Москва, Россия

O N Khokhlova

ФБУН ЦНИИ эпидемиологии Роспотребнадзора

Москва, Россия

L V Serebrovskaya

ФБУН ЦНИИ эпидемиологии Роспотребнадзора

Москва, Россия

T S Guseva

ФГБУ ФНИЦЭМ им. Н.Ф. Гамалеи Минздрава России

Москва, Россия

O V Parshina

ФГБУ ФНИЦЭМ им. Н.Ф. Гамалеи Минздрава России

Москва, Россия

V V Maleev

ФБУН ЦНИИ эпидемиологии Роспотребнадзора

Москва, Россия

References

  1. Yang Y, Zhou Y, Hou J, Bai C, Li Z, Fan J, Ng IO, Zhou W, Sun H, Dong Q, Lee JM, Lo CM, Man K, Yang Y, Li N, Ding G, Yu Y, Cao X. Hepatic IFIT3 predicts interferon-α therapeutic response in patients of hepatocellular carcinoma. Hepatology. 2017. https://doi.org/10.1002/hep.29156
  2. Boisvert M, Shoukry NH. Type III interferons in hepatitis C virus infection. Front Immunol. 2016;7:628. https://doi.org/10.3389/fimmu.2016.00628
  3. Lin Z, Zhang J, Ma X, Yang S, Tian N, Lin X, Zhou S, Liu L, Gao Y. The Role of Interferon Lambda 3 Genetic Polymorphisms in Response to Interferon Therapy in Chronic Hepatitis B Patients: An Updated Meta-Analysis. Hepat Mon. 2016;16(7): e37534. https://doi.org/10.5812/hepatmon.37534
  4. Tillmann HL, Thompson AJ, Patel K, Wiese M, Tenckhoff H, Nischalke HD, Lokhnygina Y, Kullig U, Göbel U, Capka E, Wiegand J, Schiefke I, Güthoff W, Grüngreiff K, König I, Spengler U, McCarthy J, Shianna KV, Goldstein DB, McHutchison JG, Timm J, Nattermann J; German Anti-D Study Group. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology. 2010;139:1586-1592. https://doi.org/1592e1581.10.1053/j.gastro.2010.07.005
  5. Chen CL, Huang JY, Wang CH, Tahara SM, Zhou L, Kondo Y, Schechter J, Su L, Lai MM, Wakita T, Cosset FL, Jung JU, Machida K. Hepatitis C virus has a genetically determined lymphotropism through co-receptor B7.2. Nat Commun. 2017;8:13882. https://doi.org/10.1038/ncomms13882
  6. Sinha M, Rao CR, Premalata CS, Shafiulla M, Lakshmaiah KC, Jacob LA, Babu GK, Viveka BK, Appaji L, Subramanyam JR. Plasma Epstein-Barr virus and Hepatitis B virus in non-Hodgkin lymphomas: Two lymphotropic, potentially oncogenic, latently occurring DNA viruses. Indian J Med Paediatr Oncol. 2016; 37(3):146-151. https://doi.org/10.4103/0971-5851.190353
  7. Kuo M-T, Hu T-H, Lu S-N, Hung CH, Wang J-H, Chen C-H, Chiu Y-C, Lee C-M. Neutrophil-to-lymphocyte ratio as a predictor of response to peginterferon plus ribavirin therapy for chronic hepatitis C. Disease Markers. 2014;2014:462958. https://doi.org/10.1155/2014/462958
  8. Gomez D, Farid S, Malik H Z, Young AL, Toogood GJ, Lodge JPA, Prasad KR. Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World Journal of Surgery. 2008;32(8):1757-1762. https://doi.org/10.1007/s00268-008-9552-6
  9. Chen T-M, Lin C-C, Huang P-T, Wen C-F. Neutrophil-to-lymphocyte ratio associated with mortality in early hepatocellular carcinoma patients after radiofrequency ablation. Journal of Gastroenterology and Hepatology. 2012;27(3):553-561. https://doi.org/10.1111/j.1440-1746.2011.06910.x
  10. Karasu Z, Tekin F, Ersoz G, Gunsar F, Batur Y, Ilter T, Akarca US. Liver fibrosis is associated with decreased peripheral platelet count in patients with chronic hepatitis B and C. Dig Dis Sci. 2007;52(6):1535-1539. https://doi.org/10.1007/s10620-006-9144-y
  11. Al-Qahtani A, Al-Anazi M, Abdo AA, Sanai FM, Al-Hamoudi W, Alswat KA, Al-Ashgar HI, Khan MQ, Albenmousa A, Khalaf Nisreen, Viswan N, Al-Ahdal MN. Correlation between genetic variations and serum level of interleukin 28B with virus genotypes and disease progression in chronic hepatitis C virus infection. Journal of Immunology Research. 2015;2015:768470. https://doi.org/10.1155/2015/768470
  12. Depla M, Pelletier S, Bedard N, Brunaud C, Bruneau J, Shoukry NH. IFN-lambda3 polymorphism indirectly influences NK cell phenotype and function during acute HCV infection. Immun Inflamm Dis. 2016;4:376-388. https://doi.org/10.1002/iid3.122
  13. Dolganiuc A, Kodys K, Marshall C, Saha B, Zhang S, Bala S, et al. Type III interferons, IL-28 and IL-29, are increased in chronic HCV infection and induce myeloid dendritic cell-mediated FoxP3+ regulatory T cells. PLoS One. 2012;7:e44915. https://doi.org/10.1371/journal.pone.0044915
  14. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399-401. https://doi.org/10.1038/nature08309
  15. Langhans B, Kupfer B, Braunschweiger I, Arndt S, Schulte W, Nischalke HD, et al. Interferon-lambda serum levels in hepatitis C. J Hepatol. 2011;54:859-865. https://doi.org/10.1016/j.jhep.2010.08.020
  16. Torres C, Brahm J, Venegas M. Lambda interferon serum levels in patients with chronic hepatitis C virus infection according to their response to therapy with pegylated interferon and ribavirin. J Interferon Cytokine Res. 2014;34:106-110. https://doi.org/10.1089/jir.2013.0005
  17. Nguyen KB, Watford WT, Salomon R, Hofmann SR, Pien GC, Morinobu A, Gadina M, O’Shea JJ, Biron CA. Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection. Science. 2002;297:2063-2066. https://doi.org/10.1126/science.1074900
  18. Pien GC, Nguyen KB, Malmgaard L, Satoskar AR, Biron CA. A unique mechanism for innate cytokine promotion of T cell responses to viral infections. J Immunol. 2002;169:5827-5837. https://doi.org/10.4049/jimmunol.169.10.5827
  19. Донцов Д.В., Романова Е.Б., Амбалов Ю.М. Метод альтернативного анализа Вальда как способ прогноза прогрессирования заболевания у больных хроническим гепатитом С. Кубанский научный медицинский вестник. 2011;4(127):69-71. Ссылка активна на: 21.05.2017. Доступно по: http://cyberleninka.ru/article/n/metod-alternativnogo-analiza-valda-kak-sposob-prognoza-progressirovaniya-zabolevaniya-u-bolnyh-hronicheskim-gepatitom-s
  20. Weng HL, Wang BE, Jia JD, Wu WF, Xian JZ, Mertens PR, Cai WM, Dooley S. Effect of interferon-gamma on hepatic fibrosis in chronic hepatitis B virus infection: a randomized controlled study. Clin Gastroenterol Hepatol. 2005;3(8):819-828. https://doi.org/10.1016/s1542-3565(05)00404-0
  21. Muir AJ, Sylvestre PB, Rockey DC. Interferon gamma-1b for the treatment of fibrosis in chronic hepatitis C infection. J Viral Hepat. 2006;13(5):322-328. https://doi.org/10.1111/j.1365-2893.2005.00689.x
  22. Knight B, Lim R, Yeoh GC, Olynyk JK. Interferon-gamma exacerbates liver damage, the hepatic progenitor cell response and fibrosis in a mouse model of chronic liver injury. J Hepatol. 2007;47(6):826-833. https://doi.org/10.1016/j.jhep.2007.06.022

Copyright (c) 2017 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies